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 Promoting health and preventing disease are common 
endeavours of all physicians. Juan Gérvas reminds us again 
that prevention should only be implemented if there is high 
quality evidence that the benefits of prevention surpass its 
harms.1 He also reminds us of the ethical and epidemiologi- 
cal differences between the curative and preventive con-
tract,2–4 and these differences are worth emphasising. 
 In curative medicine, harm and benefit coexist in the 
same patient. Consider treatment with nonsteroidal anti-in-
flammatory drug (NSAIDs) for rheumatoid arthritis. The pa-
tient who has an NSAID-induced GI-bleeding is the same 
that experienced a reduction in arthritis symptoms. Contrast 
this with lung cancer screening. The individual whose life 
is saved by earlier detection of her lung cancer is not the 
same individual who requires a bronchoscopy to exclude 
cancer after a false-positive screening test. So, a preventive 
intervention may have a favourable benefit harm balance 
at the population level, but the individual patient we offered 
prevention can suffer net harm.2 This is a first argument to 
support the idea that preventive interventions need high 
quality evidence that they are safe. 
 One of the teachings of clinical epidemiology is that the 
probability of benefiting from an intervention depends on 
the baseline risk of a poor outcome. Consider acetylsalicylic 
acid (ASA) for prevention of cardiovascular disease.5 In 
people with previous cardiovascular events, for every 1000 
patients treated with ASA for 10 years, 150 avert a second 
cardiovascular event. Contrast this with people with no pre-
vious cardiovascular events. For every 1000 people treat-
ed with ASA for 10 years, 6 avert a second cardiovascular 
event. A striking difference from curative to preventive med-
icine is that the percentage of patients that benefit from a 
curative treatment is much larger than the percentage of pa-
tients that benefit from a preventive treatment. In addition, 
it is estimated that for 1000 people treated with ASA for 10 
years, 3 will experience a major gastrointestinal bleeding. It 
becomes clear that the larger the baseline risk of cardiovas-
cular event, the more favourable is the balance of benefits 
and harms antiplatelet treatment with ASA. This relationship 
is valid for most preventive interventions. This is a second 
argument to support the idea that preventive interventions 
need high quality evidence that they are safe. 
 In clinical practice it is easy to forget the differences be-
tween the curative and preventive contract, especially now 
when the lines between and the other are blurred (e.g. the 
treatment of hypertension, osteoporosis, cervical intraep-
ithelial neoplasia). We should thank Juan Gérvas for this 
opportunity to pause and think about our everyday practice.
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